EcoDrugPlus

Fibroblast Growth Factor 2

Ensembl ID : ENSUAMG00000022594
Gene Symbol: FGF2
1 Cross references
114 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSUAMG00000018748
Gene Symbol: FGFR1
2 Cross references
289 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSUAMG00000017700
Gene Symbol: FGFR2
2 Cross references
216 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSUAMG00000008801
Gene Symbol: FGFR3
2 Cross references
196 Possible Orthologues:

Fibroblast Growth Factor Receptor 4

Ensembl ID : ENSUAMG00000027912
Gene Symbol: FGFR4
2 Cross references
123 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSUAMG00000023232
Gene Symbol: FLT1
2 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSUAMG00000023222
Gene Symbol: FLT3
2 Cross references
133 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSUAMG00000004369
Gene Symbol: FLT4
2 Cross references
195 Possible Orthologues:

Folate Receptor Alpha

Ensembl ID : ENSUAMG00000027376
Gene Symbol: FOLR1
2 Cross references
217 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSUAMG00000020253
Gene Symbol: FSHR
2 Cross references
199 Possible Orthologues:

Free Fatty Acid Receptor 1

Ensembl ID : ENSUAMG00000020738
Gene Symbol: FFAR1
2 Cross references
138 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSUAMG00000020734
Gene Symbol: FFAR2
2 Cross references
331 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).